One unexpected AE occurred during the study: a subject from the comparator group experienced a markedly elevated ALT level and was diagnosed with hepatitis A. The subject was excluded from the third vaccination to eliminate the possibility of confounding the assessment of safety following subsequent vaccinations. This evidence concerns the gene GPT and hepatitis A virus infection.